Table 1. Main clinical data of patients according to the compensated or decompensated stage of cirrhosis.
| Compensated patients (n = 88) | Decompensated patients (n = 131) | P | |
|---|---|---|---|
| Age, years | 52 (46–58) | 50 (44–56) | 0.12 |
| Male, n (%) | 78 (88.6) | 123 (93.9) | 0.21 |
| Abstinence during follow-up, n (%) | 60 (68.2) | 76 (58.0) | 0.16 |
| Number of previous decompensation events, n (%) | |||
| None | 88 (100.0) | 18 (13.7) | |
| 1 | - | 100 (76.3) | |
| 2 | - | 8 (6.1) | |
| ≥3 | - | 5 (3.9) | |
| Types of previous decompensation events, n (%) | |||
| Ascites | - | 32 (24.5) | |
| Hepatic encephalopathy | - | 9 (6.9) | |
| Variceal bleeding | - | 54 (41.2) | |
| Multiple events | - | 17 (13.0) | |
| WBC, mm-3 | 4940 (4030–6827) | 4940 (3430–6130) | 0.18 |
| Platelet count, 109/L | 154 (96–233) | 123 (80–178) | 0.01 |
| AST, IU/L | 51 (32–73) | 62 (42–84) | 0.03 |
| ALT, IU/L | 29 (19–49) | 23 (15–41) | 0.04 |
| GGT, U/L | 290 (117–433) | 188 (91–433) | 0.14 |
| Albumin, g/dL | 3.6 (3.3–3.9) | 3.2 (3.0–3.6) | < 0.001 |
| Bilirubin, mg/dL | 0.8 (0.5–1.4) | 1.3 (0.7–2.3) | < 0.001 |
| Prothrombin time, INR | 1.0 (0.9–1.1) | 1.1 (1.0–1.3) | < 0.001 |
| Creatinine, mg/dL | 0.6 (0.5–0.8) | 0.7 (0.6–0.8) | 0.5 |
| Spleen diameter, cm | 10.7 (9.7–11.8) | 12.0 (10.7–13.8) | < 0.001 |
| Child-Pugh class, n (%) | < 0.001 | ||
| A | 74 (84.1) | 56 (42.7) | |
| B | 14 (15.9) | 65 (49.6) | |
| C | 0 | 10 (7.6) | |
| MELD score | 8 (7–10) | 10 (8–13) | < 0.001 |
| HVPG, mmHg | 9 (6–13) | 15 (11–18) | < 0.001 |
| Esophageal varices, n (%) | < 0.001 | ||
| None | 60 (68.2) | 36 (27.5) | |
| Small | 21 (23.9) | 41 (31.3) | |
| Medium | 5 (5.7) | 49 (37.4) | |
| Large | 2 (2.3) | 5 (3.8) | |
| Gastric varices, n (%) | 0.01 | ||
| None | 74 (84.1) | 87 (66.4) | |
| Small | 10 (11.4) | 27 (20.6) | |
| Medium | 4 (4.5) | 14 (10.7) | |
| Large | 0 | 3 (2.3) | |
| High-risk varices, n (%) | 10 (11.4) | 63 (48.1) | < 0.001 |
| Charlson Comorbidity Index | 1 (1–2) | 3 (2–3) | < 0.001 |
| Prophylactic treatment, n (%) | < 0.001 | ||
| Beta-blockers | 39 (44.3) | 85 (64.9) | |
| Band ligation | 1 (1.1) | 2 (1.5) | |
| Both beta-blockers and band ligation | 0 | 30 (22.9) |
Data are median (interquartile range) or number (%), unless otherwise indicated.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MELD, model of end-stage liver disease.